CD8A and colorectal carcinoma: The combination of high CD8+ T-lymphocyte fraction and low stroma fraction can identify a subgroup with a 5-year TTR rate was 64% (95% CI 56–73) from this conventionally accepted high-risk stage ΙΙΙ CRC, even although the patients in the QUASAR 2 study received only single-agent capecitabine.